Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Gulseren Demir Karakilic

ClinicalTrials.gov lists Gulseren Demir Karakilic as lead sponsor of 10 trials.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Disease areas Disease areas 20 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 3 Journals published in Journals published in 18 Latest dated events Latest dated events 10 Disease areas Disease areas 20 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 3 Journals published in Journals published in 18 Latest dated events Latest dated events 10

Rows recorded per section

20 sections measured, none recorded

This page covers Gulseren Demir Karakilic: 10 lead-sponsored trials and 0 legal-entity registrations.

Get the Gulseren Demir Karakilic report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (20)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Anxiety Disorders 5
Pain 3
Temporomandibular Joint Disorders 3
Arthritis, Rheumatoid 2
Chronic Pain 2

Trials by start year as sponsor or collaborator (3)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 1
2025 6
2024 3

No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

Journals published in (18)

Shown in this order: most published in first.

Journals published in
Journal Publications
Rheumatology international 3
Annals of the rheumatic diseases 2
Acta psychiatrica Scandinavica 1
Agri : Agri (Algoloji) Dernegi'nin Yayin organidir = The journal of the Turkish Society of Algology 1
Archives of rheumatology 1

Latest dated events (10)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-01-06 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-07-03 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-07-03 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-06-19 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-05-22 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, biomarker capability evidence, and biomarkers this organization publishes on.